Improving
Patient Outcomes
At AAT Wound Care, our mission is to revolutionize wound care through providing advanced solutions that enhance wound repair and improve patient outcomes.
We are leading supplier of advanced wound care products, such as amniotic membrane allografts, which support chronic wound care applications, and provide protection to damaged tissue.
Understanding the Burden of Chronic Wounds
Chronic wounds, which fail to progress through the healing stages within 30 days, pose significant risks and burdens to both patients and healthcare systems. Innovative treatments and comprehensive care are essential to improving patient outcomes and quality of life.1
5-year Mortality (%), of Diabetic Foot Complications Comparable to Cancer 2
The Cost of Diabetic Limb Complications is more than the Cost of Five of the Most Deadly Cancers in the US (Billion)2
6.5 Million
Conditions such as diabetes, varicose veins, smoking, obesity, and aging can impede healing, leading to chronic wounds that currently affect approximately 10.5 million patients over the age of 65 in the U.S. alone.3
$25 Billion
Сontributes to over $25 Billion in annual healthcare expenses, and the allocation of substantial healthcare resources.4
20 Seconds
Every 20 seconds a lower limb is amputated due too complications of diabetes.5
85%
Of all lower extremity amputations in a persons with diabetes, 85% are preceded by a foot ulcer.5
Do you have access to the environment and treatments you need to manage chronic wounds?
Percent Change in Wound Area of Diabetic Foot Ulcers Over a 4-week Period 7
- Effective management of chronic wounds involves a timely and accurate diagnosis, regular debridement, infection control, and the use of the right advanced wound care solutions.1
- Providers at the forefront of innovation re-evaluate wound progress every 30 days, to see and assess alternate treatment modalities and wound care technologies.1
- Common chronic wound treatments include dressings, antimicrobials, negative pressure wound therapy (NPWT), bioengineered skin grafts, hyperbaric oxygen pressure, and cellular, and acellular matrix-like products.6
- Studies show that Cellular, acellular, and matrix-like products, such as amniotic membranes (AM), are a potential solution to these challenges. A growing body of evidence suggests that Amniotic Membrane (AM) allografts may be useful for treatment-resistant wounds.6
Addressing these conditions early with the right tools and treatment settings is crucial for improving the wound repair rate and patient discomfort. In fact:
Studies show that subjects with a reduction in ulcer area greater than the four-week median had a 12-week healing rate of 58%, whereas those with a reduction in ulcer area less than the four-week median had a healing rate of only 9% (P<0.01).7
Our Comprehensive Provider Support
Our Advanced Wound Care Solutions
Ready to improve your patient
outcomes and quality of life?
Antimicrobial Technologies LLC